Article
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
Blood - 17 Feb 2022
You Xiaona, Liu Fabao, Binder Moritz, Vedder Alexis, Lasho Terra, Wen Zhi, Gao Xin, Flietner Evan, Rajagopalan Adhithi, Zhou Yun, Finke Christy, Mangaonkar Abhishek, Liao Ruiqi, Kong Guangyao, Ranheim Erik A, Droin Nathalie, Hunter Anthony M, Nikolaev Sergey, Balasis Maria, Abdel-Wahab Omar, Levine Ross L, Will Britta, Nadiminti Kalyan Vara Ganesh, Yang David, Geissler Klaus, Solary Eric, Xu Wei, Padron Eric, Patnaik Mrinal M, Zhang Jing
Abstract excerpt
Mutations in chromatin regulator ASXL1 are frequently identified in myeloid malignancies, in particular ∼40% of patients with chronic myelomonocytic leukemia (CMML). ASXL1 mutations are associated with poor prognosis in CMML and significantly co-occur with NRAS mutations. Here, we show that concurrent ASXL1 and NRAS mutations defined a population of CMML patients who had shorter leukemia-free survival than those...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.